Kuros Biosciences (XSWX:KURN) Accounts Payable & Accrued Expense : CHF1.30 Mil (As of Dec. 2023)

View and export this data going back to 2002. Start your Free Trial

What is Kuros Biosciences Accounts Payable & Accrued Expense?

Kuros Biosciences's quarterly accounts payable & accrued expense declined from Dec. 2022 (CHF1.30 Mil) to Jun. 2023 (CHF1.19 Mil) but then increased from Jun. 2023 (CHF1.19 Mil) to Dec. 2023 (CHF1.30 Mil).

Kuros Biosciences's annual accounts payable & accrued expense increased from Dec. 2021 (CHF0.85 Mil) to Dec. 2022 (CHF1.30 Mil) but then declined from Dec. 2022 (CHF1.30 Mil) to Dec. 2023 (CHF1.30 Mil).

Kuros Biosciences Accounts Payable & Accrued Expense Historical Data

The historical data trend for Kuros Biosciences's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kuros Biosciences Accounts Payable & Accrued Expense Chart

Kuros Biosciences Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Accounts Payable & Accrued Expense

Get a 7-Day Free Trial

1.06

0.94

0.85

1.30

Kuros Biosciences Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Accounts Payable & Accrued Expense	Get a 7-Day Free Trial															0.85	0.92	1.30	1.19	1.30

Kuros Biosciences Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

Kuros Biosciences (XSWX:KURN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Kuros Biosciences Ltd (XSWX:KURN) » Definitions » Accounts Payable & Accrued Expense

Comparable Companies

Traded in Other Exchanges

CSBTF:USA KURNz:UK

Address

Wagistrasse 25, Schlieren, Zurich, CHE, 8952

Website

https://www.kurosbio.com

Kuros Biosciences Ltd is a Swiss-based biopharmaceutical company focused on the development of innovative products for tissue repair and bone regeneration. It operates through the following segments: Medical devices, Pharmaceuticals and Legacy portfolio. The Medical devices segment includes products such as MagnetOs and Attrax. The Pharmaceuticals segment includes products such as Fibrin-PTH, a drug-biologic combination that promotes targeted and controlled bone formation through the induction of osteoprogenitor cell differentiation, enhancement, of osteoblast proliferation and increasing the lifespan of bone-forming cells. The Legacy portfolio segment includes all other products that do not belong to the group's core business strategy.

Kuros Biosciences (XSWX:KURN) Headlines

No Headlines